Equities research analysts at Cantor Fitzgerald upped their target price on shares of Celldex Therapeutics (NASDAQ: CLDX) from $16.00 to $24.00 in a research note issued to investors on Monday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 12.83% from the stock’s previous close.
EricRutanski
Hey you can follow EXCO's acquisition from Chesapeake over here...watch the Live Streaming Transcript of this event http://www.earningsimpact.com/Stream.aspx?ID=N1%2ba3fKQ6gs%3d&Ticker=XCO
2013-07-08 10:18